Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
For catheter ablation
The PulseSelect™ pulsed field ablation (PFA) system is a cardiac ablation system that enables both mapping and precise lesion delivery using biphasic waveform optimization.
The PulseSelect™ PFA system is setting a new standard in safety for paroxysmal and persistent atrial fibrillation ablation supported by 15 years of robust preclinical and clinical evidence. The PulseSelect PFA system offers a differentiated approach to pulsed field ablation that can be implemented across workflows, driving safe, effective, and efficient procedures.1
Engineered with differentiated safety features from 15 years of PFA research and backed by one of the safest investigational device exemption (IDE) AF ablation trials to date.
Rapid, effective pulmonary vein isolation (PVI)1 through consistent and predictable energy delivery and catheter maneuverability.
Seamless transition to PFA with freedom to adapt to your preferred workflow.
Fixed electrode spacing to produce a reliable field for predictable and consistent contiguous energy delivery.
20-degree forward tilt to ensure more consistent uniform tissue contact.
PULSED AF evaluated the safety and effectiveness of the PulseSelect™ PFA system for the treatment of patients with paroxysmal and persistent atrial fibrillation and resulted in one of the lowest safety event rates of any AF ablation IDE trial to date.
0.7%
(primary safety event rate*)
70%
PAF
(freedom from AF/AFL/AT)
62%
PsAF
(freedom from AF/AFL/AT)
*Total of 13 adverse events measured; resulted in one cerebrovascular accident and one tamponade.
Visit Medtronic Academy
Verma A, Haines DE, Boersma LV, et al. Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation. May 9, 2023;147(19):1422–1432.
Medtronic data on file. November 2023.